![Fig. 2. Area under the pupil size–over–time curve [AUEpupil (0–12)] for the 12-h period after the administration of loperamide (32 mg) and either placebo or tariquidar. There was no significant decline in AUEpupilafter tariquidar ( P = 0.11).](https://asa2.silverchair-cdn.com/asa2/content_public/journal/anesthesiology/109/6/10.1097_aln.0b013e31818d8f28/2/23ff2.png?Expires=1716615862&Signature=x3ZnMthLa-lRrfyYEi-DbYFDZiMXZiM~LqkSxhsVPzDSY3nAz2Uw~KC1i76DckbmVZcQi9UmYr0iLtnbrvEtbVtAW8TC8BW2EeRlo7BQ66wRWfBrxJfHstaRSPss47~24MpPXZTb9AmR8ZzLspl8tHpVEbH1EYDiXFf83dKD6y~ajnpl98nbx2NsIRg8beF80w7ce6rCI1RO2j5KW877ziPEjp3zte3u4YKR75CRFSzVsD273GrSrh4wcuQS~y~Z9~t4rXv1X~xBQsCYp7D57vHNTXHVZIyEwNEkq2pNjdvVOxwsG-v5OR3fiZHEQj2lhwJ5cDA43S6kI6XaqVtqsg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Fig. 2. Area under the pupil size–over–time curve [AUEpupil (0–12)] for the 12-h period after the administration of loperamide (32 mg) and either placebo or tariquidar. There was no significant decline in AUEpupilafter tariquidar ( P = 0.11).
Fig. 2. Area under the pupil size–over–time curve [AUEpupil (0–12)] for the 12-h period after the administration of loperamide (32 mg) and either placebo or tariquidar. There was no significant decline in AUEpupilafter tariquidar ( P = 0.11).
